Achieve Life Sciences (ACHV) Price & Analysis

Compare

1,718 Followers

ACHV Stock Chart & Stats

$4.46

-$0.11(-3.08%)

At close: Jan 08 4:00 PM EST

$4.46

-$0.11(-3.08%)

Day’s Range― - ―

52-Week Range$1.84 - $5.78

Previous CloseN/A

Volume131.37K

Average Volume (3M)582.41K

Market Cap

$229.97M

Enterprise Value$122.55M

Total Cash (Recent Filing)$48.11M

Total Debt (Recent Filing)$9.96M

Price to Earnings (P/E)―

Beta1.96

Next Earnings

Mar 12, 2026

EPS Estimate

-0.28

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.28

Shares Outstanding53,233,990

10 Day Avg. Volume491,436

30 Day Avg. Volume582,413

Financial Highlights & Ratios

PEG Ratio0.16

Price to Book (P/B)5.40

Price to Sales (P/S)0.00

P/FCF Ratio-3.79

Enterprise Value/Market Cap0.53

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-1.05K

Enterprise Value/Ebitda-2.39

Forecast

1Y Price Target

$15.33

Price Target Upside243.72% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)-1.26

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessCytisinicline demonstrated positive results in the P3 ORCA-2 study, achieving significant rates of smoking cessation compared to placebo without serious treatment-related adverse events.

Market PotentialCytisinicline is expected to be the first FDA-approved drug for smoking cessation in 20 years, highlighting its potential to fill a significant gap in the market.

Regulatory AdvancementsAchieve Life Sciences received an FDA Commissioner's National Priority Voucher for cytisinicline in e-cig/vaping cessation, allowing for expedited FDA review and potential earlier market entry.

Bears Say

Commercial RisksRisks to the thesis include commercial execution risk, clinical trial risk, regulatory risk, financing risk, and the potential need for a partner.

Financial PerformanceAchieve Life Sciences reported a net loss of $14.4M for 3Q25, which may concern some investors despite other positive developments.

Achieve Life Sciences News

Achieve Life Sciences initiated with an Outperform at Citizens JMP

Citizens JMP analyst Jason Butler initiated coverage of Achieve Life Sciences (ACHV) with an Outperform rating and $19...

29d ago

ACHV

Promising Developments and Strategic Advancements Drive Positive Outlook for Achieve Life Sciences

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Achieve Life Sciences. The associated price...

2M ago

ACHV

Positive Outlook for Achieve Life Sciences: Buy Rating Backed by Promising Regulatory Progress and Market Potential

JonesTrading analyst Justin Walsh has reiterated their bullish stance on ACHV stock, giving a Buy rating yesterday. Justin...

2M ago

ACHV

Achieve Life Sciences Reports Q3 2025 Results

Achieve Life Sciences ( ($ACHV) ) has released its Q3 earnings. Here is a breakdown of the information...

2M ago

ACHV

Achieve Life Sciences: Key Insights from Earnings Call

Achieve Life Sciences (($ACHV)) has held its Q3 earnings call. Read on for the main highlights of the...

2M ago

ACHV

Achieve Life Sciences: Advancements in Cytisinicline Propel Buy Rating Amid Regulatory Milestones and Clinical Success

H.C. Wainwright analyst Brandon Folkes has reiterated their bullish stance on ACHV stock, giving a Buy rating on...

2M ago

ACHV

Achieve Life Sciences reports Q3 EPS (28c), consensus (26c)

“The FDA’s acceptance of our NDA for cytisinicline in smoking cessation is an important milestone for Achieve, reflecting...

2M ago

ACHV

ACHV Earnings this Week: How Will it Perform?

Achieve Life Sciences (ACHV) is scheduled to report 3rd quarter earnings on 11/06/2025, before the market opens. Regarding...

2M ago

ACHV

Achieve Life Sciences announces several milestones in its ORCA-OL trial

Achieve Life Sciences (ACHV) announced several milestones in its ORCA-OL long-term safety trial supporting the New Drug Application,...

2M ago

ACHV

Achieve Life Sciences appoints Atkisson as Chief Legal Officer

Achieve Life Sciences (ACHV) announced the appointment of Erik Atkisson as Chief Legal Officer. In his new role,...

2M ago

ACHV

Morning Movers: Regional banks in focus after reporting Q3 results

Stock futures are mixed in early trading amid growing concerns over regional banks’ exposure to bad loans and...

2M ago

AXP

Achieve Life Sciences receives FDA CNPV for cytisinicline

Achieve Life Sciences (ACHV) announced that the U.S. Food and Drug Administration has awarded the company a Commissioner’s...

2M ago

ACHV

Achieve Life Sciences: Promising Prospects in Vaping Addiction Treatment with Cytisinicline

Brandon Folkes, an analyst from H.C. Wainwright, maintained the Buy rating on Achieve Life Sciences. The associated price...

2M ago

ACHV

Achieve Life Sciences Announces Leadership Change

Achieve Life Sciences ( ($ACHV) ) has provided an update. On September 11, 2025, Achieve Life Sciences announced...

3M ago

ACHV

ACHV FAQ

What was Achieve Life Sciences Inc’s price range in the past 12 months?

Achieve Life Sciences Inc lowest stock price was $1.84 and its highest was $5.78 in the past 12 months.

What is Achieve Life Sciences Inc’s market cap?

Achieve Life Sciences Inc’s market cap is $229.97M.

When is Achieve Life Sciences Inc’s upcoming earnings report date?

Achieve Life Sciences Inc’s upcoming earnings report date is Mar 12, 2026 which is in 79 days.

How were Achieve Life Sciences Inc’s earnings last quarter?

Achieve Life Sciences Inc released its earnings results on Nov 06, 2025. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.244 by -$0.036.

Is Achieve Life Sciences Inc overvalued?

According to Wall Street analysts Achieve Life Sciences Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Achieve Life Sciences Inc pay dividends?

Achieve Life Sciences Inc does not currently pay dividends.

What is Achieve Life Sciences Inc’s EPS estimate?

Achieve Life Sciences Inc’s EPS estimate is -0.28.

How many shares outstanding does Achieve Life Sciences Inc have?

Achieve Life Sciences Inc has 53,233,990 shares outstanding.

What happened to Achieve Life Sciences Inc’s price movement after its last earnings report?

Achieve Life Sciences Inc reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.244. Following the earnings report the stock price went down -3.854%.

Which hedge fund is a major shareholder of Achieve Life Sciences Inc?

Currently, no hedge funds are holding shares in ACHV

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Achieve Life Sciences Stock Smart Score

Outperform

Fundamentals

Return on Equity

-161.08%

Trailing 12-Months

Asset Growth

8.60%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Achieve Life Sciences Inc

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

Achieve Life Sciences (ACHV) Earnings & Revenues

Historic Earnings Reports

ACHV Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted significant regulatory achievements and strategic advancements, particularly in gaining an expedited review for vaping cessation. However, funding needs for further clinical trials and challenges in aligning commercial strategies for two different market entries pose potential risks.View all ACHV earnings summaries

ACHV Stock 12 Month Forecast

Average Price Target

$15.33

▲(243.72% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","6":"$6","11":"$11","16":"$16","21":"$21"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,6,11,16,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.12,6.264615384615385,7.409230769230769,8.553846153846154,9.698461538461538,10.843076923076923,11.987692307692306,13.132307692307691,14.276923076923076,15.42153846153846,16.566153846153846,17.71076923076923,18.855384615384615,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.12,5.905384615384616,6.690769230769231,7.476153846153847,8.261538461538462,9.046923076923077,9.832307692307694,10.617692307692309,11.403076923076924,12.188461538461539,12.973846153846154,13.759230769230768,14.544615384615387,{"y":15.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.12,5.495384615384616,5.8707692307692305,6.246153846153846,6.621538461538462,6.996923076923077,7.372307692307692,7.747692307692308,8.123076923076923,8.498461538461537,8.873846153846154,9.24923076923077,9.624615384615385,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.71,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.38,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.52,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.27,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.07,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.51,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.9,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.92,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.1,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.12,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >